1
Appendix 1: Draft Eligibility Criteria
2
Level 1 screening
3
1. Does this study include adult patients (aged ≥ 18 years) with type 1 diabetes?
4
5
6
7
8
9
10
YES____
NO____
2. Is this an experimental, quasi-experimental observational study (cohort), or costing studies?
YES____
NO____
YES____
NO____
UNCLEAR____
Trade name(s) of insulin
Levemir
Lantus
4. Does the study compare long acting insulin analogues compared to long acting insulin or intermediate
acting insulin preparations or placebo?
YES____
NO____
Generic name of insulin
Isophane insulin (neutral
protamine Hagedorn, NPH)
Zinc insulin (lente)
Insulin detemir (long acting)
Insulin glargine (long acting)
17
18
19
20
UNCLEAR____
3. Are patients treated with long acting basal insulin analogue preparations?
Generic name of insulin
Insulin detemir
Insulin glargine
11
12
13
14
15
16
UNCLEAR____
UNCLEAR____
Trade name(s) of insulin
Novolin N, Humulin N
Humulin L, Novolin L
Levemir
Lantus

If you answer NO to any of these questions, the citation/study will be excluded. All other
citations will be included.
1
21
Level 2 screening
22
1. Does this study include adult patients (aged ≥ 18 years) with type 1 diabetes?
23
24
25
26
27
28
29
YES____
NO____
UNCLEAR____
2. Is this an experimental, quasi-experimental, observational study (cohort), or costing studies?
YES____
NO____
UNCLEAR____
3. Are patients treated with long acting basal insulin analogue preparations?
YES____
NO____
UNCLEAR____
Generic name of insulin
Insulin detemir
Insulin glargine
30
31
32
33
34
35
Trade name(s) of insulin
Levemir
Lantus
4. Does the study compare long acting insulin analogues compared to long acting insulin or intermediate
acting insluin preparations or placebo?
YES____
NO____
UNCLEAR____
Generic name of insulin
Trade name(s) of insulin
Novolin N, Humulin N
Isophane insulin (neutral
protamine Hagedorn, NPH)
Zinc insulin (lente)
Insulin detemir (long acting)
Insulin glargine (long acting)
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
Humulin L, Novolin L
Levemir
Lantus
5. Does the study report at least one of the following outcomes?
Glycosylated hemoglobin (A1C); emergency department visits for hypo/hyperglycemia, physician visits
for hypo/hyperglycemia, hospital admissions for hypo/hyperglycemia, weight gain, quality of life,
microvascular complications (retinopathy, neuropathy, nephropathy), macrovascular complications
(cardiovascular disease, stroke/transient ischemic attack, peripheral vascular disease), all-cause mortality,
incident cancers, cost or cost-effectiveness.
YES____
NO____
UNCLEAR____
 If you answer NO to any of these questions, the citation/study will be excluded. All other full-text
articles will be included.
2
51
52
Appendix 2: Draft MEDLINE literature search
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
exp Diabetes Mellitus, Type 1/ [ Type 1 Diabetes Mellitus ]
exp Diabetic Ketoacidosis/
T1DM.tw,ot.
IDDM.tw,ot.
(insulin adj depend$).tw,ot.
insulin-depend$.tw,ot.
insulin?depend$.tw,ot.
("typ$ 1" adj2 diabet$).tw,ot.
("typ$ I" adj2 diabet$).tw,ot.
("typ$ 1" adj2 DM).tw,ot.
("typ$ I" adj2 DM).tw,ot.
(acidos$ adj2 diabet$).tw,ot.
(juvenil$ adj2 diabet$).tw,ot.
(child$ adj2 diabet$).tw,ot.
(keto$ adj2 diabet$).tw,ot.
(labil$ adj2 diabet$).tw,ot.
(britt$ adj2 diabet$).tw,ot.
(earl$ adj2 diabet$).tw,ot.
(p?ediatric adj2 diabet$).tw,ot.
(acidos$ adj2 DM).tw,ot.
(juvenil$ adj2 DM).tw,ot.
(child$ adj2 DM).tw,ot.
(keto$ adj2 DM).tw,ot.
(labil$ adj2 DM).tw,ot.
(britt$ adj2 DM).tw,ot.
(earl$ adj2 DM).tw,ot.
(p?ediatric adj2 DM).tw,ot.
(auto-immun$ adj2 diabet$).tw,ot.
(autoimmun$ adj2 diabet$).tw,ot.
("sudden onset" adj2 diabet$).tw,ot.
(auto-immun$ adj2 DM).tw,ot.
(autoimmun$ adj2 DM).tw,ot.
("sudden onset" adj2 DM).tw,ot.
("insulin$ defic$" adj2 absolut$).tw,ot.
or/1-34
Insulin, Long-Acting/ [ long-acting insulin terms ]
Insulin/aa [Analogs & Derivatives]
Hypoglycemic Agents/
(antidiabetic adj agent?).tw,ot.
(anti-diabetic adj agent?).tw,ot.
(antidiabetic adj drug?).tw,ot.
(anti-diabetic adj drug?).tw,ot.
antidiabetics.tw,ot.
3
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
anti-diabetics.tw,ot.
(antihyperglyc?emic adj agent?).tw,ot.
(anti-hyperglyc?emic adj agent?).tw,ot.
antihyperglyc?emics.tw,ot.
anti-hyperglyc?emics.tw,ot.
(hypoglyc?emic adj drug?).tw,ot.
(hypo-glyc?emic adj drug?).tw,ot.
(hypoglyc?emic adj effect?).tw,ot.
(hypo-glyc?emic adj effect?).tw,ot.
hypoglyc?emics.tw,ot.
hypo-glyc?emics.tw,ot.
(longacting adj2 insulin$).tw,ot.
("long acting" adj2 insulin$).tw,ot.
("longacting" adj2 analog$).tw,ot.
("long acting" adj2 analog$).tw,ot.
(semilente adj insulin$).tw,ot.
(insulin$ adj2 analog$).tw,ot.
(insulin$ adj2 derivativ$).tw,ot.
lantus.mp. [ Glargine ]
optisulin.mp.
Gly$A21.mp.
A21Gly$.mp.
(gly$ adj1 A21).mp.
HOE-901.mp.
HOE901.mp.
SoloStar.mp.
glargin$.mp.
glargine.rn. [ CAS Registry Number ]
detemir.mp. [ Detemir ]
levemir.mp.
NN 304.mp.
LS-186557.mp.
detemir.rn. [ CAS Registry Number ]
or/36-76
exp Adult/ [ validated geriatric filter - best sensitivity ]
adult.mp. [ validated adult filter - best sensitivity ]
Middle Aged/
age$.tw.
or/78-81
35 and 77 and 82
exp Animals/ not (Humans/ and exp Animals/)
83 not 84
4